Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...
N. Zacharias, Eric S Rupe, Xinyue Chen et al.· Clinical Cancer Research· 0 citations
Abstract Background There is a need for novel systemic therapies in patients with metastatic renal cell carcinoma (RCC) who progress on standard agents. A hallmark of clear cell RCC (ccRCC) is von Hippel Lindau (VHL) inactivation which affects downstream targets including vascular endothelial growth factor (VEGF). It a...
Sahil D. Doshi, Y. Ged, Andrea Knezevic et al.· The Oncologist· 0 citations
MSK-Tox provides an empirical basis for a new precision safety paradigm for predicting who will be harmed by a therapy on the same principles that guide prediction of therapeutic benefit, and identifies two modes of germline susceptibility to treatment toxicity.
Z. Bakouny, X. Guo, F. Huang et al.· medRxiv· 0 citations
Using large, unselected pan-cancer cohorts and integrated tumor and genomic analysis can help refine the phenotype of rare cancer predisposition syndromes and suggest novel cancer associations, including BAP1 PVs in hepatobiliary cancers and FLCN in colorectal cancer.
M. Carlo, Andrew Schroeder, Jie Liu et al.· Journal of the National Canc...· 0 citations
An atlas of ccRCC tumors is assembled combining single-cell RNA sequencing and imaging-based spatial transcriptomics to suggest reversion to embryonic nephrogenesis as a defining feature of persister cells in ccRCC, nominating the nephrogenic developmental program and its associated inhibitory checkpoint repertoire as...
The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors and had manageable safety and encouraging antitumor activity in CD70-positive ccRCC.
S. Srour, J. Chahoud, A. Drakaki et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
